About Prof. Zhang Xing
Prof. Zhang Xing (张星) is China's preeminent medical oncologist specializing in bone and soft tissue sarcomas and malignant melanoma, serving as Chief Physician, Professor, Doctoral Supervisor, and Director of the Melanoma and Sarcoma Ward at Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou. Widely regarded as a national pioneer in rare solid tumor oncology, Prof. Zhang also serves as Deputy Group Leader of the Chinese Society of Clinical Oncology (CSCO) Soft Tissue Sarcoma Guidelines Working Group.
Sarcomas encompass over 70 distinct, biologically heterogeneous, and frequently treatment-refractory subtypes. Prof. Zhang has devoted his career to transforming sarcoma management from empirical chemotherapy to precision-targeted therapy and novel immuno-oncology combinations, establishing SYSUCC as the foremost referral destination for complex and heavily pre-treated sarcoma patients across China and Asia.
Core Clinical Specializations & Oncological Innovations
1. Bone and Soft Tissue Sarcomas
Prof. Zhang commands unparalleled expertise across the full spectrum of soft tissue and bone malignancies, including liposarcoma, leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma (UPS), rhabdomyosarcoma, angiosarcoma, and osteosarcoma. His clinical practice integrates deep genomic sequencing with subtype-specific treatment algorithms, selecting targeted multi-kinase inhibitors, anti-angiogenic agents, and novel epigenetic modulators tailored to each tumor's unique driver mutations.
2. Malignant Melanoma (Cutaneous, Acral & Mucosal)
In Asian populations, melanoma frequently manifests as acral lentiginous or mucosal subtypes, which exhibit distinctive genetic landscapes (such as KIT and CCND1 alterations) and lower responsiveness to standard anti-PD-1 monotherapy compared to Western cutaneous melanoma. Prof. Zhang is an internationally recognized expert in customizing combination protocols—integrating targeted kinase inhibitors with dual immune checkpoint blockade, anti-VEGF therapies, and regional strategies—to overcome therapeutic resistance and dramatically improve response rates.
3. Sarcoma Immunotherapy Combinations & Resistance Reversal
While sarcomas were traditionally viewed as immunologically "cold" tumors, Prof. Zhang has led the clinical development of synergistic immunotherapy combinations. By pairing immune checkpoint inhibitors with anti-angiogenic targeted agents (such as tyrosine kinase inhibitors), metronomic chemotherapy, or novel immunomodulators, his clinical protocols reprogram the immunosuppressive tumor microenvironment, achieving sustained tumor regressions in patients whose disease progressed on standard anthracycline-based regimens.
4. MDT Leadership for Complex & Refractory Solid Tumors
As chief medical oncologist for sarcoma and melanoma at SYSUCC, Prof. Zhang leads multidisciplinary tumor boards (MDTs) coordinating surgical oncologists, radiation therapists, interventional radiologists, and specialized musculoskeletal pathologists. This collective approach delivers personalized, organ-preserving, and limb-salvage treatment strategies for retroperitoneal tumors, pelvic sarcomas, and multifocal metastatic presentations.
Academic Leadership, Research & Landmark Publications
Prof. Zhang is an internationally celebrated clinical investigator whose translational discoveries consistently reshape clinical practice in rare cancer oncology:
- High-Impact Publications: As corresponding author, Prof. Zhang has published numerous landmark papers in prestigious oncology journals, including Molecular Cancer, eClinicalMedicine (Part of The Lancet Discovery Science), British Journal of Cancer (BJC), and the Journal for ImmunoTherapy of Cancer (JITC).
- CSCO National Guidelines Leadership: Serving as Deputy Group Leader of the CSCO Soft Tissue Sarcoma Guidelines Working Group, Prof. Zhang plays a foundational role in authoring and updating China's national clinical treatment pathways and standard-of-care guidelines.
- Pioneering Multicenter Clinical Trials (2024–2025): Prof. Zhang acts as Principal Investigator (PI) leading multiple multicenter Phase I, II, and III clinical trials testing novel antibody-drug conjugates (ADCs), next-generation immune checkpoint agonists, bispecific antibodies, and targeted compounds specifically targeting refractory sarcoma subtypes.
Sun Yat-sen University Cancer Center (SYSUCC) Profile
Sun Yat-sen University Cancer Center in Guangzhou is officially recognized as a National Cancer Center and consistently ranks among China's top three specialized oncology institutions. Its dedicated Melanoma and Sarcoma Ward, led by Prof. Zhang Xing, represents one of the largest and most specialized clinical inpatient units of its kind worldwide, providing patients with access to advanced molecular pathology laboratories, dedicated clinical trial wards, and comprehensive multidisciplinary support.
Why International Patients Seek Care with Prof. Zhang Xing
- Subtype-Specific Precision Medicine: Rather than applying "one-size-fits-all" regimens, Prof. Zhang analyzes exact molecular signatures to pair rare sarcoma and melanoma variants with targeted therapeutics.
- Direct Pathway to Novel Clinical Trials: For patients who have exhausted standard chemotherapy options, Prof. Zhang's active clinical trial portfolio provides access to experimental compounds and combination therapies.
- Expertise in Acral and Mucosal Melanoma: World-leading experience in managing non-cutaneous and Asian-predominant melanoma subtypes that are rarely encountered in standard Western clinics.
- Cost-Effective, World-Class Care: Access to cutting-edge targeted therapies, immunotherapies, and comprehensive inpatient management at significantly lower costs than comparable Western tertiary centers.
The Patient Journey: Navigating Care with CMCS
China Medical Concierge – Shanghai (CMCS) provides overseas patients with direct, coordinated access to Prof. Zhang Xing and the specialized sarcoma/melanoma clinical teams at SYSUCC in Guangzhou:
- Step 1: Pathology & Genomic Review: Patients submit biopsy reports, unstained pathology slides/blocks, and genetic sequencing panels for preliminary verification by specialized sarcoma pathologists.
- Step 2: Clinical Feasibility & Trial Pre-Screening: We coordinate an expert clinical review with Prof. Zhang's team to assess treatment eligibility, potential targeted regimens, or clinical trial matching.
- Step 3: Visa Assistance & Travel Logistics: CMCS handles medical visa documentation, Guangzhou airport meet-and-greet, private transfers, and comfortable lodging arrangements near the cancer center.
- Step 4: On-Site Medical Translation & Ward Support: Dedicated bilingual medical liaisons accompany you through outpatient consultations, hospital admission, diagnostic tests, and treatment infusions.
- Step 5: Follow-Up & Global Coordination: Following discharge, CMCS maintains communication between your home oncologists and Prof. Zhang's team to monitor ongoing response and lab values.
Frequently Asked Questions
Are sarcomas responsive to immunotherapy?
While single-agent immunotherapy has modest efficacy in unselected sarcomas, combination regimens pioneered by Prof. Zhang—combining anti-PD-1 antibodies with targeted anti-angiogenic agents—have demonstrated significant clinical activity and durable tumor shrinkage in subtypes such as alveolar soft part sarcoma, undifferentiated pleomorphic sarcoma, and synovial sarcoma.
What options exist after standard chemotherapy failure in soft tissue sarcoma?
Patients with disease progression after first-line anthracycline-based chemotherapy are evaluated for secondary targeted agents (e.g., anlotinib, pazopanib, regorafenib), novel antibody-drug conjugates (ADCs), or targeted clinical trials led by Prof. Zhang.
How does mucosal or acral melanoma treatment differ from cutaneous melanoma?
Acral and mucosal melanomas have lower tumor mutational burden and fewer BRAF V600E mutations, but higher rates of KIT, CDK4, and CCND1 alterations. Prof. Zhang utilizes customized combination protocols designed specifically to address these biological pathways.
How long should international patients plan to stay in Guangzhou?
Comprehensive diagnostic restaging and MDT consultation typically require 3 to 5 business days. If systemic infusion therapy or clinical trial enrollment is initiated, patients usually remain in Guangzhou for 2 to 3 weeks for cycle administration and observation.
Schedule Your Consultation with Prof. Zhang Xing
If you or a loved one is facing bone sarcoma, soft tissue sarcoma, or malignant melanoma, our medical concierge team is ready to coordinate your consultation and medical review.
Contact CMCS Medical Concierge:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
댓글 0개